Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1Approved for marketing 1

Sponsor Class

OTHER 20INDUSTRY 3OTHER_GOV 1NIH 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Other neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 3210Carcinoma, Non-Small-Cell Lung 2721Breast Neoplasms 2547Colorectal Neoplasms 1454Prostatic Neoplasms 1303Neoplasm Metastasis 1292Multiple Myeloma 1109Melanoma 1101Ovarian Neoplasms 1001Lung Neoplasms 941Recurrence 921Leukemia, Myeloid, Acute 876Pancreatic Neoplasms 830Lymphoma, Non-Hodgkin 766Lymphoma 713Stomach Neoplasms 691Carcinoma, Renal Cell 658Carcinoma, Hepatocellular 645Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 546Lymphoma, Follicular 515Head and Neck Neoplasms 488Glioblastoma 472Small Cell Lung Carcinoma 444Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 433Advanced Solid Tumors 430Leukemia 426Uterine Cervical Neoplasms 418Urinary Bladder Neoplasms 405

Interventions

pirtobrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Syndrome × Clear all
NCT07216443 2026-04-15

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Orca Biosystems, Inc.

Phase 2 Recruiting
80 enrolled
MyeloidOther hematologic neoplasmOther neoplasm

Acute Disease, Bone Marrow Diseases, Disease, Graft vs Host Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Precancerous Conditions, Preleukemia, Syndrome, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Disease Attributes

NCT05172700 2024-12-18

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Eli Lilly and Company

Approved for marketing
LymphoidOther hematologic neoplasm

Hematologic Diseases, Waldenstrom Macroglobulinemia, Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04155190 2023-05-31

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Sol-Gel Technologies, Ltd.

Phase 2 Terminated
47 enrolled
Dermatologic

Rombo syndrome, Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Syndrome, Xeroderma Pigmentosum

Data powered by HemOnc (CC BY 4.0) Colophon âš¡